Study of IL-23 inhibitors for inflammatory bowel disease
Part of Digestive system clinical trials.
This study looks at how safe and effective a new type of medicine, called IL-23 inhibitors, is for people with ulcerative colitis or Crohn's disease. If you're starting this treatment for the first time, this study may help us learn more about how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with ulcerative colitis or Crohn's disease.
- Your doctor has decided that you should start taking an IL-23 inhibitor for the first time.
- You are not currently in another clinical study, and you don't plan to join one during this study.
- You do not have any medical conditions that make IL-23 inhibitors unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody drug (IL-23 inhibitor) for people with Crohn's disease or ulcerative colitis. It aims to see if the drug is safe and effective. You may be able to join if you have moderate to severe disease and have not had certain bowel surgeries or infections.
This study follows patients with moderate-to-severe Crohn's disease who are starting a newer type of biologic medication called IL-23 inhibitors (guselkumab or risankizumab). Researchers want to understand how well these drugs work in real-world clinical practice and compare their effectiveness to other treatments.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This study tracks how well guselkumab (a biologic medication that blocks IL-23, a protein that drives inflammation) works for moderate-to-severe ulcerative colitis or Crohn's disease in everyday clinical practice. Researchers want to understand long-term benefits and safety in real patients.
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
This Phase 4 trial tests which type of biologic medicine works best as the first treatment for people with moderate-to-severe Crohn’s that mainly affects the ileum. It may help you and your care team choose a more effective first option, based on which strategy leads to better control of symptoms and intestinal inflammation.
Hear when a new Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.